Sage Therapeutics, Inc. (SAGE)’s Trend Down, Especially After Forming a Wedge Down Chart Pattern

May 18, 2018 - By Margarite Burden

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Investors sentiment increased to 1.49 in Q4 2017. Its up 0.28, from 1.21 in 2017Q3. It increased, as 27 investors sold Sage Therapeutics, Inc. shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported.
Aqr Management Limited Liability holds 48,010 shares. Pictet Asset Management Ltd has invested 0.2% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Voloridge Invest Ltd Liability invested in 0.19% or 53,908 shares. Gam Holding Ag reported 55,300 shares. 10 were reported by Pnc Financial Svcs Gp. Dekabank Deutsche Girozentrale has 63,450 shares. Mutual Of America Mngmt Llc accumulated 0.09% or 35,365 shares. 17,079 are owned by Voya Inv Mgmt Ltd Company. Envestnet Asset Management Inc holds 0% or 2,624 shares in its portfolio. Balyasny Asset Limited Company accumulated 261,200 shares or 0.13% of the stock. Ra Capital Limited Liability has invested 6.27% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Amalgamated Natl Bank owns 0.02% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 5,147 shares. Moreover, Jpmorgan Chase has 0.03% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Wellington Mngmt Ltd Liability Partnership accumulated 2.07M shares. Fernwood Inv Lc reported 8,466 shares stake.

Since December 14, 2017, it had 0 insider buys, and 6 sales for $42.42 million activity. 59,000 Sage Therapeutics, Inc. (NASDAQ:SAGE) shares with value of $9.96M were sold by STARR KEVIN P. 60,000 shares valued at $9.57M were sold by Robichaud Albert on Thursday, December 14. 58,139 Sage Therapeutics, Inc. (NASDAQ:SAGE) shares with value of $10.00M were sold by PAUL STEVEN M. Another trade for 7,000 shares valued at $1.08M was made by FRATES JAMES M on Tuesday, May 8. Kanes Stephen sold $7.80M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, January 10.

The stock of Sage Therapeutics, Inc. (SAGE) formed a down wedge with $153.97 target or 7.00 % below today’s $165.56 share price. The 9 months wedge indicates high risk for the $7.70 billion company. If the $153.97 price target is reached, the company will be worth $539.07M less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 5.57% or $9.77 during the last trading session, reaching $165.56. About 568,473 shares traded or 19.01% up from the average. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since May 18, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on August, 2. They expect $-1.87 earnings per share, up 0.53 % or $0.01 from last year’s $-1.88 per share. After $-1.68 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.31 % negative EPS growth.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 10 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SAGE Therapeutics has $277.0 highest and $178.0 lowest target. $216.86’s average target is 30.99% above currents $165.56 stock price. SAGE Therapeutics had 13 analyst reports since December 7, 2017 according to SRatingsIntel. As per Monday, April 23, the company rating was maintained by BMO Capital Markets. The stock has “Buy” rating by Canaccord Genuity on Monday, March 26. The stock has “Buy” rating by Leerink Swann on Thursday, December 7. Stifel Nicolaus maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Thursday, December 7. Stifel Nicolaus has “Buy” rating and $198.0 target. The company was maintained on Wednesday, January 31 by BMO Capital Markets. As per Thursday, February 22, the company rating was maintained by RBC Capital Markets. The stock has “Buy” rating by Cowen & Co on Thursday, December 7. SunTrust maintained the shares of SAGE in report on Thursday, December 7 with “Buy” rating. The company was upgraded on Thursday, December 7 by Chardan Capital Markets. The company was maintained on Thursday, December 7 by BMO Capital Markets.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Nasdaq.com which released: “Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today” on April 20, 2018, also Businesswire.com with their article: “Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” published on May 03, 2018, Streetinsider.com published: “SAGE Therapeutics (SAGE) Defended at Raymond James, Says Selloff is Overreaction” on April 20, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Streetinsider.com and their article: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” published on May 15, 2018 as well as Seekingalpha.com‘s news article titled: “Key events next week – healthcare” with publication date: April 20, 2018.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.70 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.